Investigational drug · Phase 2
CAB-AXL-ADC
Also called: BA3011
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-Small-Cell Lung Cancer, Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 25, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
3
Any phase or sponsor naming "CAB-AXL-ADC"
First trial start
2018
Feb 15, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CAB-AXL-ADC", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Small-Cell Lung Cancer
- Undifferentiated Pleomorphic Sarcoma
- Myxofibrosarcoma
Largest trials
Live from ClinicalTrials.gov: studies naming "CAB-AXL-ADC" as an intervention, largest first.
BioAtla, Inc.Industry
NCT03425279 · 245 participants · Start Feb 15, 2018 · Primary completion Jan 8, 2025
Drug: CAB-AXL-ADC; PD-1 inhibitor · For: Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma
Sites: Tucson, Arizona; Los Angeles, California; San Francisco, California · 40 sites in all
BioAtla, Inc.Industry
NCT04681131 · 85 participants · Start Mar 17, 2021 · Primary completion Jul 9, 2025
Drug: CAB-AXL-ADC; PD-1 inhibitor · For: Non-Small-Cell Lung Cancer
Sites: Duarte, California; Irvine, California; Los Angeles, California · 60 sites in all
Canadian Cancer Trials GroupResearch network
NCT04918186 · 60 participants (planned) · Start May 3, 2022 · Primary completion Dec 31, 2026
Drug: Durvalumab; BA3011 and 3 more · For: Ovarian Cancer
Sites: Chicago, Illinois; Kelowna, Canada; Vancouver, Canada · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- CRI-CCTG-0003/IND.240 an immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC): Sub-studies A and B: Durvalumab (D) + mecbotamab vedotin (BA3011) or ozuriftamab vedotin (BA3021).
MacKay HJ, Tinker AV, Nelson BH, et al. · Cancer Treat Res Commun 2026
- Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody-drug conjugate.
Chang HW, Wang J, Liu H, et al. · Antib Ther 2025
Also in development for Non-Small-Cell Lung Cancer
- AndamertinibPLB1004Phase 38 trials
Avistone Biotechnology Co., Ltd. · Non-Small-Cell Lung Cancer, NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer
- VebreltinibPLB1001Phase 36 trials
Avistone Biotechnology Co., Ltd. · Non-Small-Cell Lung Cancer, Glioblastoma, Non-Small Cell Lung Cancer
- FirmonertinibAST2818Phase 34 trials
Allist Pharmaceuticals, Inc. · Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer
- ImzokitugBMS-986340Phase 22 trials
Bristol Myers Squibb · Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC), Cervical Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.